Company Overview of PanGenetics B.V.
PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases, cancer, and pain. The company develops a portfolio of antibody drugs through in-licensing model. Its products pipeline includes PG102-Prototype, an original chimeric anti-CD40 antibody; PG102, a CD40 antagonist; PG110, an anti-nerve growth factor antibody for use in chronic pain; PG130, an undisclosed therapeutic antibody; and PG140, an antagonist of CD86. The company was formerly known as Tanox Pharma B.V. The company was founded in 1995 and is based in Utrecht, the Netherlands with an additional office in Cambridge, the United Kingdom. PanGenetics B.V. is a former subsidiary of Tanox Inc.
Founded in 1995
31 30 253 7911
31 30 253 3967
Key Executives for PanGenetics B.V.
PanGenetics B.V. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Farallone Therapeutics B.V.||Europe|
|Boehringer Ingelheim B.V.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact PanGenetics B.V., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.